BRISBANE, Calif. — November 24, 2025 — Leads & Copy — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.
The management team will present at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, in Coral Gables, FL, and the Citi 2025 Global Healthcare Conference on Wednesday, December 3, 2025, in Miami, FL. Both events will feature a fireside chat format and one-on-one meetings.
The Evercore Healthcare Conference presentation will take place at 8:45 a.m. ET, and the Citi Global Healthcare Conference presentation will be at 4:00 p.m. ET.
Webcasts of the presentations will be available. The Evercore Healthcare Conference webcast can be accessed at https://wsw.com/webcast/evercore52/vera/2362844, and the Citi Global Healthcare Conference webcast can be accessed at https://kvgo.com/global-healthcare-conference-2025/vera-therapeutics-december-2025.
Replays of the webcasts will be available for 90 days on the Vera Therapeutics website in the “Investor Calendar” section.
Vera Therapeutics is focused on developing treatments for serious immunological diseases, with a mission to advance treatments targeting the source of disease. The company’s lead product candidate is atacicept, a self-administered subcutaneous injection that blocks both BAFF and APRIL, reducing autoantibodies that contribute to autoimmune diseases such as IgAN and lupus nephritis. Vera Therapeutics is also evaluating atacicept for additional diseases.
Vera Therapeutics holds an exclusive license agreement with Stanford University for VT-109, a next-generation fusion protein targeting BAFF and APRIL. VT-109 has therapeutic potential across B-cell mediated diseases. The company is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can affect kidney transplant recipients.
The company retains all global developmental and commercial rights to atacicept, VT-109, and MAU868.
Joyce Allaire, Investor Contact, LifeSci Advisors, 212-915-2569, jallaire@lifesciadvisors.com
Debra Charlesworth, Media Contact, Vera Therapeutics, 415-854-8051, corporatecommunications@veratx.com
Source: Vera Therapeutics
